Magazine article Clinical Psychiatry News

[H.Sub.2]-Blocker Appears to Cut Atypical Weight Gain

Magazine article Clinical Psychiatry News

[H.Sub.2]-Blocker Appears to Cut Atypical Weight Gain

Article excerpt

No impact on therapeutic response.

PHOENIX, ARIZ. -- Using a [histamine.sub.2] blocker may attenuate the weight gain associated with atypical antipsychotics, according to a poster presentation at the annual meeting of the New Clinical Drug Evaluation Unit sponsored by the National Institute of Mental Health.

In a double-blind, placebo-controlled study that looked at the effects of adding the [H.sub.2]-blocker nizatidine to olanzapine, weight gain was lower and was observed to plateau more quickly with the higher dose of nizatidine. The addition of the [H.sub.2]-blocker had no impact on therapeutic response or on other adverse events, said. Dr. Alan Brier of Lilly Research Laboratories, Indianapolis.

Weight gain with atypical antipsychotics--as observed in an analysis of data from a large international trial of olanzapine--can be substantial. Although patients participating in the study averaged 14 pounds of weight gain, some gained considerably more. The increase typically reaches a plateau after 9 months of treatment, the investigators noted.

The possible efficacy of an [H.sub.2]-blocker in forestalling weight gain has been suggested by case reports in which cimetidine reduced appetite and weight in healthy overweight individuals and those with type 2 diabetes mellitus. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.